Experimental HIV Drugs
Experimental HIV Drugs
6. HIV Drugs: Few New Approvals, but Pipeline Looks Promising
- Details
- Category: Approved HIV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
HIV drug development news in 2014 included approval of a new single-tablet regimen and 2 more components of antiretroviral therapy (ART). Promising candidates in the pipeline include a better-tolerated version of tenofovir, a NNRTI with fewer neuropsychiatric side effects, and potential long-acting injectables that may be useful for treatment or pre-exposure prophylaxis.
European Commission Approves Boosted Darunavir Combo Rezolsta for HIV
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 09 December 2014 00:00
- Written by Janssen
The European Commission last month approved a new fixed-dose coformulation -- dubbed Rezolsta -- containing the HIV protease inhibitor darunavir boosted with the novel pharmacoenhancer cobicistat, Janssen recently announced. The combination is currently being evaluated for U.S. approval.
Gilead Submits Request for FDA Approval of Tenofovir Alafenamide Coformulation
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 06 November 2014 00:00
- Written by Gilead Sciences
Gilead Sciences this week announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-tablet regimen containing tenofovir alafenamide (TAF) -- a new version of the widely used antiretroviral that causes less kidney and bone toxicity -- coformulated with its new integrase inhibitor elvitegravir, cobicistat, and emtricitabine.
HIV Drug Therapy: Doravirine Works as Well as Efavirenz with Fewer CNS Side Effects
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 07 November 2014 00:00
- Written by Liz Highleyman
Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side effects, researchers reported this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.
HIVR4P 2014: Injectable Rilpivirine Shows Promise, May Work Better for Anal than Vaginal Sex
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 04 November 2014 00:00
- Written by Gus Cairns
A Phase 1 dose-finding and safety study in humans of TMC278-LA, a long-acting, injectable formation of the antiretroviral drug rilpivirine, found that a single 1200 mg dose could produce sustained drug levels in rectal tissues that could offer protection against HIV for 3 months, and did in fact suppress viral replication in so-called explants (biopsies of rectal mucosal cells) for that length of time. However -- and to the surprise of researchers presenting this study at the HIV Research for Prevention conference last week in Cape Town -- drug levels in vaginal and cervical cells were only about half of those seen in rectal cells, and viral replication was not suppressed in vaginal and cervical biopsies taken from women given TMC278-LA.
More Articles...
- IDWeek 2014: HIV Attachment Inhibitor BMS-663068 Works Well Across Patient Subgroups
- FDA Approves Elvitegravir and Cobicistat Booster as Stand-alone Drugs
- Tenofovir Alafenamide Pill Matches Stribild, Gilead Will Seek Approval Soon
- ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster
Web Design and Development by